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Impaired use of the upper limb is one of the most common symptoms after stroke, and improving upper limb function 
is a priority for many patients.1 Clinical trials of increased 
dose of upper extremity task-specific training have been dis-
appointing.2 This suggests new interventions are needed to 
maximize poststroke motor recovery.3
Vagus nerve stimulation (VNS) paired with movement has 
been shown to drive task-specific plasticity in the motor cortex 
in rodent models and improve forelimb function after experi-
mental stroke.4 In our first-in-human, randomized, controlled, 
open clinical trial, VNS paired with upper limb rehabilitation 
was safe and feasible in people with upper limb deficit at least 
6 months after ischemic stroke.5
The purpose of this pilot study was to further assess 
safety, feasibility, and efficacy of VNS paired with upper limb 
rehabilitation in chronic ischemic stroke, with blinded, sham 
VNS control.
Methods
This article adheres to the American Heart Association Journals’ 
implementation of the Transparency and Openness Promotion 
Guidelines. Requests for data will be considered by the corresponding 
author after Food and Drug Administration postmarket approval.
This was a randomized, sham stimulation controlled, and fully 
blinded study of VNS paired with rehabilitation in people with arm 
weakness after ischemic stroke. Participants in both groups were 
implanted with the VNS device. Participants, therapists, and outcome 
assessors were blinded to group allocation.
The study was approved by an institutional review board at each 
institution and subject to appropriate regulatory approvals (Food and 
Drug Administration investigational device exemption No. 130287 and 
UK Medicines and Healthcare Products Regulatory Agency [MHRA] 
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No. CI/2015/0011). It was registered on http://www.clinicaltrials.gov 
(NCT02243020). Written informed consent was obtained in compliance 
with the requirements set forth in US Food and Drug Administration, 
Code of Federal Regulations Title 21. The study was conducted accord-
ing to the Declaration of Helsinki.
Participants
Enrollment at the 4 sites is shown in Table I in the online-only Data 
Supplement. People with a history of unilateral supratentorial ischemic 
stroke that occurred between 4 months to 5 years before randomization, 
aged ≥30 and ≤80 years, and with an FMA-UE between 20 to 50 were 
eligible for inclusion (Table II in the online-only Data Supplement).
Protocol Summary
A presurgery assessment was performed. After VNS implantation 
and ≈1 week of recovery, participants were randomized to either 
active VNS (0.8 mA) or control VNS (0.0 mA), and baseline assess-
ments were repeated. In-clinic rehabilitation therapy began on the 
next day and was delivered ≈3× a week for 6 weeks (18 visits; 
Figure I in the online-only Data Supplement). Outcomes assess-
ments were performed on days 1, 7, 30, and 90 after completion of 
in-clinic therapy.
After 6 weeks of in-clinic therapy, all participants began daily, 
therapist-prescribed home exercises. For the first 30 days of at-home 
therapy, all participants received 0 mA VNS. Thereafter, participants 
received VNS according to their randomized allocation. After the 
day-90 assessment, the control VNS group crossed over to receive 
6 weeks of in-clinic rehabilitation paired with active VNS (0.8 mA) 
followed by outcome assessments at days 1, 7, 30, and 90 thereafter.
Further details on methodology are given in Appendix in the 
online-only Data Supplement.
Main Study Outcome Measures
The main safety outcome measure was the number of serious adverse 
events related to the device or therapy. The main feasibility measure 
was the number of participants who completed the minimum number 
of visits during the randomized portion of the study (at least 12 
therapy visits).
Efficacy outcomes included the FMA-UE,6 Wolf Motor 
Function Test (WMFT; time and functional), Box and Block Test, 
Nine-Hole Peg Test, Stroke Impact Scale, and Motor Activity Log. 
Because this was a pilot study, no primary or secondary efficacy 
measures were designated.
Sample Size and Statistical Analysis
No formal sample size calculation was performed for this pilot study. 
Efficacy analyses were performed on the intention-to-treat popula-
tion and included all randomized participants. Missing data were not 
imputed. The change in outcome measures at each time point was 
compared between groups using 2-tailed, unpaired t tests. Fisher 
exact test was used to calculate the significance for response rates. 
For all comparisons, α was set at 0.05.
Figure 1. Fugl-Meyer assessment–upper extremity (FMA-UE; mean±SEM) and Wolf Motor Function Test (WMFT) scores (mean±SEM). A, Change in FMA-UE 
score during blinded follow-up for active vagus nerve stimulation (VNS) and controls from baseline and 3 posttreatment assessments. B, Change in FMA-UE 
score following crossover to active VNS. C, Change in WMFT functional score during blinded follow-up for active VNS and controls. D, Change in WMFT 
score following crossover to active VNS. Shaded area indicates the 6 wk of in-clinic therapy. Rebase, baseline in controls before starting active VNS. Days 1 
to 30 (after in-clinic therapy) consisted of at-home therapy with no VNS for both groups. From days 30 to 90, active VNS group received VNS (0.8 mA) and 
controls received control VNS (0 mA) with at-home therapy. *P=0.029 at post-90 d and P<0.001 at post-30 d.
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Results
Twenty-two people consented to participate in the study. Of 
these, 17 participants were implanted and randomized (8 
to active VNS and 9 to control; Figure II in the online-only 
Data Supplement). All participants completed the randomized 
portion of the study. Baseline characteristics of participants 
are shown in Table III in the online-only Data Supplement. 
Details on protocol adherence, feasibility, and blinding are 
provided in the online-only Data Supplement.
Safety
There were 3 serious adverse events related to implantation 
surgery, including 1 implantation wound infection requiring 
treatment with intravenous antibiotics but resolved; 1 case 
of shortness of breath and dysphagia, likely because of in-
tubation, which recovered; and 1 case of hoarseness because 
of vocal cord palsy. There were no serious adverse events 
reported as associated with stimulation. Full details of ad-
verse events are shown in Appendix in the online-only Data 
Supplement.
Efficacy
Between-group differences in FMA-UE are shown in 
Figure 1 and the Table. At day 90, the response rate (defined 
as FMA-UE change ≥6 points7) was 88% in the active group 
and 33% in control (P=0.03; Figure 2). Between-group differ-
ences in Wolf Motor Function Test are shown in Figure 1 and 
the Table.
After crossover to active VNS in controls, FMA-UE 
scores increased to 9.8 points above baseline at day 1 after in-
clinic therapy (P<0.001) and by 9.7 points at day 90 (P=0.01; 
Figure 1). Response rates were 88% and 57% at these time 
points, respectively (Figure 2). Wolf Motor Function Test data 
are shown in Figure 1. Full details on all outcome measures are 
shown in Tables V and VI in the online-only Data Supplement.
Discussion
The primary objective of this pilot study was to assess the 
safety and feasibility of using paired VNS to improve arm 
function after chronic ischemic stroke. We found this tech-
nique to be feasible, including the use of home-based VNS, 
and demonstrated safety in-line with that expected for VNS 
devices. The study was not powered to assess efficacy, al-
though there were significant differences between groups in 
some measures at day 90.
There are several important differences between this and 
our previous clinical study.5 This study was fully blinded, all 
participants were implanted with a VNS device, control par-
ticipants crossed over to receive the active VNS therapy, and 
participants continued rehabilitation exercises at home for 
several months.
There were no significant differences between groups im-
mediately after in-clinic therapy completion, but there was 
a significant difference by 90 days because of maintained 
benefit by the VNS group with corresponding decline in the 
control group and a higher percentage of responders who 
Table. Change in Outcome Measures (Intention-to-Treat Analysis, n=17 [Active VNS, 8; Control, 9])
Measure
Day-1 Difference Post–In-Clinic Therapy* Day-90 Difference Post–In-Clinic Therapy*
95% CI P Value 95% CI P Value
FMA-UE 2.29 (−1.9 to 6.47) 0.2604 5.72 (−0.15 to 11.6) 0.055
WMFT functional 0.12 (−0.10 to 0.33) 0.2625 0.33 (0.04 to 0.61) 0.029
WMFT time, s −3.02 (−11 to 5.24) 0.4215 −4.04 (−14 to 5.64) 0.362
Stroke Impact Scale (hand) 5.66 (−11 to 22.7) 0.4889 2.71 (−14 to 19.9) 0.741
Box and Block Test −2.93 (−6.3 to 0.44) 0.0835 −0.23 (−4.1 to 3.66) 0.903
Nine-Hole Peg Test −2.25 (−58 to 53.5) 0.9245 −9.18 (−48 to 29.2) 0.580
Motor Activity Log NA NA 17.93 (−0.37 to 36.2) 0.054
FMA-UE indicates Fugl-Meyer assessment–upper extremity; NA, not applicable; VNS, vagus nerve stimulation; and WMFT, Wolf 
Motor Function Test.
*Difference between groups: active VNS - control VNS.
Figure 2. Average Fugl-Meyer assessment–upper extremity (FMA-UE) 
response rate. A, Responder rate (defined as FMA-UE change ≥6 from 
baseline) for the first 90 d in paired vagus nerve stimulation (VNS; black) 
and controls (gray). B, Responder rates after control group crossed over 
to receive active VNS therapy. Rebase, baseline in controls before starting 
active VNS therapy. *P<0.05, Fisher exact test.
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achieved a clinically meaningful change for the FMA-UE 
(change, ≥6 points) with active VNS treatment.7 Although 
we cannot definitively conclude these differences are be-
cause of paired active VNS treatment, our findings are con-
sistent with the effect of a neuroplastic treatment where 
time may be needed for benefit to accrue. It is of note that 
control participants experienced a benefit similar to the ini-
tial VNS participants when they crossed over to active VNS 
treatment.
This pilot study showed that rehabilitation paired with 
VNS is an acceptably safe and feasible intervention for the 
treatment of upper limb weakness after ischemic stroke. The 
study demonstrated sufficient safety, feasibility, and potential 
efficacy to support a larger pivotal trial.
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